Bristol-Myers Squibb Prep Session

1
Bristol-Myers Squibb Prep Session

• Presented by
• Doug Greenberg
• Seema Katiyar
• Whitney Lesch

2
Site Visit Agenda
Topic Role of the FDA and its Relationship with
the Pharmaceutical Industry
Agenda The program will start at 830 AM.
(Please be there by 800 AM) It will end at
approximately 100 PM. Plainsboro Site
(Building 2) 200,000 sq.ft of office space
3
Mission Values
Source www.bms.com

• We pledge -- to our patients and customers, to
  our employees and partners, to our shareholders
  and neighbors, and to the world we serve -- to
  act on our belief that the priceless ingredient
  of every product is the honor and integrity of
  its maker.
• We pledge excellence in everything we make and
  market, providing the safest, most effective and
  highest-quality medicines and health care
  products. We promise to continually improve our
  products through innovation, diligent research
  and development, and an unyielding commitment to
  be the very best.
• We pledge courteous, efficient and ethical
  behavior and practices respect for your
  interests and an open door. We pledge to build
  and uphold the trust and goodwill that are the
  foundation of successful business relationships.
• We pledge personal respect, fair compensation and
  honest and equitable treatment. To all who
  qualify for advancement, we will make every
  effort to provide opportunity. We affirm our
  commitment to foster a globally diverse workforce
  and a companywide culture that encourages
  excellence, leadership, innovation and a balance
  between our personal and professional lives. We
  acknowledge our obligation to provide able and
  humane leadership and a clean and safe work
  environment.
• We pledge our dedication to responsibly
  increasing the shareholder value of your company
  based upon continued growth, strong finances,
  productive collaborations and innovation in
  research and development.
• We pledge conscientious citizenship, a helping
  hand for worthwhile causes and constructive
  action that supports a clean and healthy
  environment. We pledge Bristol-Myers Squibb to
  the highest standard of moral and ethical
  behavior and to policies and practices that fully
  embody the responsibility, integrity and decency
  required of free enterprise if it is to merit and
  maintain the confidence of our society. 

To extend and enhance human life by providing the
highest-quality pharmaceuticals and related
health care products
4
Company History
Source www.bms.com

• 1858 Edward Squibb founded a pharmaceutical
  company in Brooklyn, NY
• 1887 - William Bristol John Myers invested in
  Clinton Pharmaceutical Company in Clinton, NY
• 1899 Incorporated Bristol-Myers Company which
  went public in 1929 (NYSE)
• 1943 - acquired Cheplin Laboratories to become a
  producer of pharmaceutical products
• 1989 Bristol-Myers merged with Squibb, to form
  worlds 2nd largest pharmaceutical company at
  that time
• 2001- acquired DuPont Pharmaceuticals Company for
  7.8 billion
• 2007 - acquired Adnexus Therapeutics, developer
  of a new therapeutic class of biologics called
  Adnectins
• Jan. 2008 - sold its Medical Imaging business to
  Avista Capital Partners for 525 million cash for
  reinvestment
• June 2008 acquired Kosan Biosciences
  Incorporated for 190 mil
• Sept 2008 ImClone rejected BMS all-cash offer
  to acquire company at 62 per share

5
Current Status
Sources www.bms.com http//finance.yahoo.com/

• Headquartered in New York City
• BMY (NYSE) trading at 20.61 (09/24/08)
• Market cap 40.68B
• Sales 19.348 billion (07), 5.203 billion
  quarterly (Jun 08), Net Profit Margin 18.51
• P/E ratio 18.67
• 5 of 10 analysts firms have upgraded the stock
  and 2 have downgraded it
• Most analysts recommend hold (10/16), a few buy
  (3) and strong buy (2)
• Annual change (loss) in cash and cash equivalents
  has improved considerably since 2006 currently
  1.8b
• Quarterly change in cash and cash equivalents has
  improved from .64b (March) to 1.60b (June)

6
5-yr Stock Price
Source http//finance.yahoo.com/
7
Rankings
8
Sales Trend

• Net Sales, Billions

9
Net Income

• Net income, Millions

10
Annual Rate of Return
11
Operating Segments
Source www.bms.com

• Pharmaceutical
• global pharmaceutical/biotechnology and
  international consumer medicines business
• Nutritionals
• Mead Johnson Nutritionals
• ConvaTec
• ostomy, wound and skin care business.

12
Key Therapeutic Areas
Source www.bms.com
RD expenditure 3.3 Billion in 2007

• Cardiovascular and Metabolic diseases
• Oncology
• Inflammation
• Infectious diseases
• Nervous System
• Psychiatric disorders
• Wound care
• Nutritionals

13
Revenue by Division
Total revenue of 19.3 Billion for 2007
14
News and Events

• FDA approves ABILIFY for the acute treatment of
  manic and mixed episodes associated with bipolar
  I disorder in pediatric patients (10 to 17 years
  of age).
• Avista Capital Partners completes acquisition of
  Bristol-Myers Squibb Medical Imaging for 525
  million.
• Bristol-Myers Squibb announces filing of IPO
  Registration for Mead Johnson Nutritionals
  business unit to sell between 10-20 of the
  company.
• Bristol-Myers Squibb purchases Kosan biosciences
  for 190 million.
• Bristol-Myers Squibb to Acquire Adnexus
  Therapeutics for 415 million.
• BMS tenders offer of 60/share to buy outstanding
  83 of Erbitux partner Imclone. Imclone chairman
  Carl Icahn is shopping the company for a better
  offer.

Sources www.bms.com www.nytimes.com
15
News (continued)

• Bristol-Myers Squibb said it will eliminate about
  10 of jobs and close half its plants to shave
  1.5 billion in costs. According to the company,
  the layoffs, which began in late 2005, will be
  implemented over three years and will affect
  4,300 employees. Bristol-Myers faces a loss of
  more than 3 billion in annual revenue in 2012,
  when its blood thinner Plavix (clopidogrel
  bisulfate) loses patent protection.

Source www.nytimes.com
14
16
Alliances

• Bristol-Myers Squibb enters cardiovascular
  disease collaboration with Isis Pharmaceuticals -
  Focus on Antisense Inhibitors of PCSK9
• Bristol-Myers Squibb and Pfizer announce
  worldwide collaboration to develop and
  commercialize anticoagulant and metabolic
  compounds.
• Bristol-Myers Squibb and AstraZeneca announce
  worldwide collaboration to develop and
  commercialize diabetes compounds.
• Bristol-Myers Squibb and KAI enter global
  alliance for the commercialization of KAIs
  first-in-class drug designed to reduce heart
  attack severity.
• Bristol-Myers Squibb and PDI Biopharma enter
  global alliance for the commercialization of
  PDIs multiple myeloma drug.

Sources www.bms.com www.nytimes.com
17
Products
Cardiovascular and metabolic diseases

• Avalide and Avapro indicated for the treatment of
  hypertension. Tablets.
• Coumadin (Warfarin) anti-coagulant indicated for
  prophylaxis and/or treatment of Venous
  thrombosis, complications assoc. with atrial
  fribillation, cardiac valve replacement. Tablets.
  
• Metaglip, Glucophage XR and Glucovance indicated
  for oral antihyperglycemic for management of type
  2 diabetes.
• Plavix indicaed for reduction of
  artherothrombotic events like MI, peripheral
  arterial disease, ACS. Tablets.

Inflammation

• Orencia indicated for the treatment of
  moderate-to-severe RA.

Source www.bms.com
18
Products
Infectious Diseases

• Atriplia indicated for HIV infection in adults
• Baraclude indicated for treatment of Hepatitis B
  viral infection
• Reyataz indicated for combination treatment of
  HIV infection.

Psychiatric Disorders

• Abilify indicated for the treatment of
  schizophrenia and bipolar disorder

Nutritionals

• Enfamil infant and baby formula
• Expecta Lipil

Source www.bms.com
19
Products
Oncology

• Erbitux - colorectal and head neck cancers.
  Administered intravenously.
• Ixempra -metastatic or locally advanced breast
  cancer in combination with capecitabine.
  Injections.
• Sprycel chronic myleoid lukemia (CML) resistant
  to other therapies including Imatinib and Phve
  ALLs. Tablets.

Wound Care

• Aquacel Ag indicated for use on acute and
  chronic wounds including burns, surgical wounds,
  foot/leg ulcers.
• Vesiva a new exudate management dressing for
  chronic and acute wounds.

Source www.bms.com
20
R D Pipeline
As of July 2008 Source www.bms.com
21
RD pipeline
As of July 2008 Source www.bms.com
Exploratory Development(Preclinical, Phase I,
Phase II) (continued)